a string of failures. Years of testing drugs that target amyloid buildup have not yielded significant returns, and may be squeezing out other more promising approaches [Ix4].
Medicare’s finances. Aducanumab is an incredibly expensive treatment, and could undermine an already highly weakened Medicare system.